LuBAIR™ Paradigm, a novel approach to ascribing meaning for behavioral expression in advanced neurocognitive disorder, was used to identify behavioral categories that are likely to respond to the use of atypical antipsychotics in their management.

A retrospective study.

St. Peter’s Hospital (SPH), Hamilton, Ontario, Canada.

Forty patients qualified for the study.

LuBAIR™ Inventory populated on all recruited patients on two separate occasions. The first time was within two weeks of admission and the second time was after sixty days, if they successfully de-prescribed off the AAP, or sooner, if they failed de-prescribing.

Chi-Square paired t-test and Cohen d Statistical tests were used to detect the difference in the behavioral categories between the two cohorts.

Seventeen patients were successfully de-prescribed, and twenty-three failed de-prescribing. Results on the LuBAIR™ Inventory, filled on the second occasion, in the successful de-prescribed and the failed de-prescribed groups compared using the Chi-Square Statistical test to detect the difference in the behavioral categories the two cohorts. Patients who did not have Mis-Identification Expressions (MiE) and Goal-Directed Expressions (GDE), amongst the cluster of behavioral categories in their clinical presentation, were more likely to successfully de-prescribe of AAP: X2 (1, N = 40) = 29.119 p<.0001 and X2 (1, N = 40) = 32.374, p<.0001, respectively. Alternatively, the same behavioral categories were more likely to be present in patients who failed de-prescribing: paired t-test and Cohen-d (P<0.0001).

The MIE and GDE were statistically significant, suggesting that these behaviors were more present in patients who failed de-prescribing. Atypical antipsychotics, in their role as an antipsychotic and mood stabilizer, may be used to manage Mis-Identification and Goal-Directed Expressions, respectively.